Clinical trials: Human Cancers
Advanced Solid Malignancies
Human ADME Study of [14C]-AZD1390
This is a Phase I, multicentre, single-dose, open-label study to assess the absorption, distribution, metabolism, and excretion of [14C]-AZD1390.
- Trial name
- NCT07643870
- Testing
- AZD1390
- Where
- 2 sites in United Kingdom
- Volunteers
- 8 people
- Sponsor
- AstraZeneca
Recurrent Diffuse Pontine Gliomas
Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma
This is a phase 2, single-arm, multi-center study, with a safety review component, designed to evaluate the efficacy and safety of nimotuzumab in approximately 44 patients with recurrent diffuse intrinsic pontine glioma (DIPG)…
- Trial name
- NCT00600054
- Testing
- nimotuzumab (anti EGFR humanized monoclonal antibody)
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 44 people
- Sponsor
- YM BioSciences
Multiple Myeloma
A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)
This study is a single-armed, open-label, multicenter Phase 1/2 study to evaluate the efficacy and safety of CT103A in subjects with relapsed and refractory MM.
- Trial name
- FUMANBA-1 (NCT05066646)
- Testing
- CT103A
- Where
- 14 sites in China
- Volunteers
- 132 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
Graft Vs Host Disease
Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)
To establish the safety and efficacy of two dose levels of ex-vivo cultured adult human mesenchymal stem cells (hMSCs) (Prochymal®) in participants experiencing acute GVHD, Grades II-IV, post hematopoietic stem cells (HSC)…
- Trial name
- NCT00136903
- Testing
- Prochymal® - 2 Million cells/kg, Prochymal®- 8 Million cells/kg, Methylprednisolone
- Where
- 9 sites in United States
- Volunteers
- 32 people
- Sponsor
- Mesoblast, Inc.
Locally Advanced or Metastatic Solid Tumors
Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors
This study is an Open-Label, Phase 1/2a, First-in-Human, Dose-Escalation, Dose-Expansion, and Proof-of-Concept Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single…
- Trial name
- NCT06293651
- Testing
- DA-4505, DA-4505 + Pembrolizumab
- Where
- 2 sites in South Korea
- Volunteers
- 125 people
- Sponsor
- Dong-A ST Co., Ltd.
Metastatic Breast Cancer, HER2-negative Breast Cancer
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
- Conditions
- Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
- Trial name
- TRACY-1 (NCT06590857)
- Testing
- RYZ101, Standard of Care Endocrine Therapy
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 64 people
- Sponsor
- RayzeBio, Inc.
Neoplasms
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
The purpose of this study is to assess the feasibility of subcutaneous (SC) administration of amivantamab based on safety and pharmacokinetics and determine a dose, dose regimen and formulation for amivantamab SC delivery.
- Trial name
- PALOMA (NCT04606381)
- Testing
- Ami-LC-MD, Ami-LC, Ami-HC
- Where
- 12 sites in United States, Canada and 2 more
- Volunteers
- 158 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Solid Tumor, Metastatic Solid Tumor
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.
- Trial name
- NCT05898399
- Testing
- ART6043, Olaparib
- Where
- 27 sites in United States, Spain and 1 more
- Volunteers
- 181 people
- Sponsor
- Artios Pharma Ltd
Solid Tumours
Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours
The purpose of this first-in-human study is to evaluate the safety and tolerability of escalating doses of ODM-203 in subjects with advanced solid tumours and to determine the maximum tolerated dose and dose limiting toxicities.
- Trial name
- KIDES-203 (NCT02264418)
- Testing
- ODM 203
- Where
- 8 sites in Denmark, Finland and 4 more
- Volunteers
- 84 people
- Sponsor
- Orion Corporation, Orion Pharma
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies
- Conditions
- Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
- Trial name
- Soundtrack-E (NCT06564038)
- Testing
- Surovatamig, Prednisone (or equivalent), Rituximab
- Where
- 66 sites in United States, Australia and 11 more
- Volunteers
- 408 people
- Sponsor
- AstraZeneca
Lymphoma, Non-Hodgkin
A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18
The purpose is to identify a dose of SB-485232 which is safe, tolerable and effective when used in combination with Rituximab in patients with non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT00500058
- Testing
- SB-485232, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
This open-label, randomized crossover study evaluated the quality of life, efficacy, and safety of subcutaneous Herceptin (trastuzumab) injected either into the thigh or the upper arm of participants with early HER2-positive…
- Trial name
- LISAH (NCT01928615)
- Testing
- Trastuzumab - intravenous solution, Trastuzumab - subcutaneous solution, Chemotherapy
- Where
- 2 sites in Austria
- Volunteers
- 2 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumor, Gastric Cancer
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-MAB in patients with advanced cancer
- Conditions
- Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05159440
- Testing
- TORL-2-307-MAB
- Where
- 8 sites in United States, South Korea
- Volunteers
- 70 people
- Sponsor
- TORL Biotherapeutics, LLC
Advanced Metastatic Breast Cancer
Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
This was a national, multi-center, open-label, phase IIIb trial to determine the efficacy and safety of treatment with ribociclib (LEE011) plus letrozole in patients with HR+, HER2-negative advanced (recurrent or metastatic)…
- Trial name
- NCT03096847
- Testing
- ribociclib, letrozole, goserelin
- Where
- 84 sites in Germany
- Volunteers
- 502 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Metastatic HER2+ Advanced Breast Cancer
Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.
A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Database to describe 3L and 4L real-world (rw) outcomes (e.g.
- Trial name
- NCT06961331
- Testing
- Tucatinib, Trastuzumab, Capecitabine
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Pfizer
Solid Tumours
A Phase 1 Trial of GEN1119 in Participants With Solid Tumors
The purpose of this trial is to learn about the safety and efficacy of GEN1119 when it is used for the treatment of participants with certain types of cancer. The trial has multiple parts.
- Trial name
- NCT07695831
- Testing
- GEN1119
- Where
- 8 sites in France, Japan and 1 more
- Volunteers
- 112 people
- Sponsor
- Genmab
Solid Tumor, Adult
First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors
This multicenter, open-label, first-in-human, Phase 1/2 study consists of a Part 1 (Phase 1) open-label dose escalation of EGL-001 administered as a single agent and in combination with an anti-PD(L)-1 treatment, followed by a…
- Trial name
- NCT06622486
- Testing
- EGL-001
- Where
- 8 sites in France, Spain
- Volunteers
- 50 people
- Sponsor
- Egle Therapeutics
Lymphoma, Non-Hodgkin, B-cell Lymphoma
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies.
- Conditions
- Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
- Trial name
- BAF_FRontier-1 (NCT07101328)
- Testing
- LY4152199 - IV
- Where
- 51 sites in United States, Australia and 10 more
- Volunteers
- 215 people
- Sponsor
- Eli Lilly and Company
Non-Myeloid Malignancy
Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy
This phase 3 study is aimed to evaluate the safety and efficacy of YPEG-rhG-CSF in reducing the infection manifested by febrile neutropenia in patients with non-myeloid malignancy who receiving Myelosuppressive Chemotherapy which…
- Trial name
- NCT04466137
- Testing
- YPEG-rhG-CSF, rhG-CSF/PEG-rhG-CSF
- Where
- China
- Volunteers
- 398 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.